SHELTON, CT / ACCESS Newswire / May 28, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Monday, June 16th, at 2:30pm at the BIO International Convention 2025 in Boston, MA. Event Information: Event NanoViricides Presentation at the BIO International Convention,... Read More

SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the "Company"), comments on the new COVID Vaccine policy adopted by the US FDA. The new FDA COVID Vaccine Booster Shots policy [1] is based on the findings that the groups that benefit from repeat of vaccination (i.e. booster shots) are the groups that are likely to be at risk of severe COVID disease from the... Read More

SHELTON, CT / ACCESS Newswire / May 16, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending March 31, 2025 with the Securities and Exchange Commission (SEC) on Thursday, May 15, 2025. The report can be accessed at the SEC website ( Click Here ) . NV-387 - Phase II Clinical Trial to Treat MPox Infection - Unmet Medical Need We... Read More

NanoViricides Explains Its Drug Strategy for Combating Viral Infections and Pandemics SHELTON, CT / ACCESS Newswire / May 14, 2025 / NanoViricides, Inc. , a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, explains its drug development strategy to... Read More

SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health (CNES) of the Ministry of Public Health (MSP), of the Democratic Republic of Congo (DRC). With this CNES approval, the proposed Phase II clinical trial to evaluate safety and effectiveness of NV-387 for the treatment of patients with... Read More

Shelton, Connecticut--(Newsfile Corp. - May 5, 2025) - NanoViricides, Inc. (NYSE American: NNVC), (the "Company"), a leading clinical stage global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.... Read More

SHELTON, CT / ACCESS Newswire / April 29, 2025 / NanoViricides, Inc. , a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, provides further details on its Measles drug development program herewith. Measles is likely to become endemic in the USA, according to modeling... Read More

SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc. , a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has begun evaluation of its clinical drug NV-387 for the treatment of the Measles virus. "A drug for measles is at... Read More

SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company") (NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that the viruses cannot escape, declared today that its business is not affected by the tariff policies of the US government or corresponding retaliatory policies of other governments, nor is it affected by the spending cuts being... Read More

SHELTON, CT / ACCESS Newswire / March 4, 2025 / The HHS Department Secretary Robert F. Kennedy Jr. wrote an Opinion piece in the FoxNews entitled "Measles outbreak is call to action for all of us". He identifies an important issue that, "…there is no approved antiviral for those who may be infected…" [1] . Parents of children who are suffering, and the doctors who are treating them, are frustrated with the lack of any... Read More

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu SHELTON, CT / ACCESS Newswire / February 19, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending December 31, 2024 with the Securities and Exchange Commission (SEC) on Friday, February 14, 2025. The report can... Read More

SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu virus H5N1 likely cannot escape despite its ability to mutate rapidly with genomic changes. An "opinion and analysis" article published in Scientific American on February 7 th... Read More

SHELTON, CT / ACCESS Newswire / January 29, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it is presenting today, January 29, at 11am at the MicroCap Conference 2025 in Atlantic City, NJ. Event Information: Event NanoViricides Presentation at the MicroCap Conference, Atlantic City... Read More

SHELTON, CT / ACCESS Newswire / January 27, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum antiviral drug NV-387 further into the regulatory pipeline. "NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as... Read More

SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that it is presenting at Biotech Showcase™ 2025 in San Fransisco, being held in parallel to the JP Morgan Life Sciences Conference. Event Information: Event NanoViricides Presentation at the Biotech... Read More

SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug. "Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very... Read More

SHELTON, CT / ACCESSWIRE / November 15, 2024 / SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024 with the Securities and Exchange Commission (SEC) on Thursday, November 14, 2024. The report can be accessed at the SEC website ( Click Here ). We reported that, as of... Read More

SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, will be presenting a corporate update at the Spartan Capital Investors Conference on Monday, November 4, 2024 (today) at 9:45 am. The Conference will be held... Read More

SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, will be presenting a talk at the PODD Conference on Monday, October 28th, 2024 at 345pm. The PODD Conference will be held at the Westin Boston Seaport District,... Read More

SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, was interviewed in a podcast by the PODD Conference* host. The podcast was published on October 11, 2024, on PharmaTalkRadio. The interview can be viewed at... Read More

Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, has been invited... Read More

SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2024 with the Securities and Exchange Commission (SEC) on Friday, September 27, 2024. The report can be accessed at the SEC website or by clicking here . We reported that, as of June 30, 2024, we had cash and cash equivalent... Read More

SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it has now obtained a right of first refusal (ROFR) for all antiviral drug developments from the R&D firm TheraCour Pharma, Inc. ("TheraCour"). NanoViricides has signed a broad Memorandum of Understanding Agreement (MoU) with... Read More

SHELTON, CT / ACCESSWIRE / August 26, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it is investigating the possibility of using NV-387 for the treatment of MPOX patients under the WHO MEURI protocol, in light of the recent WHO PHEIC (Public Health Emergency of International Concern) declaration for the current... Read More

SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program activities. Dr. Anil Diwan, the Company's President, and Executive Chairman, is currently visiting with various expert professionals with the objective of developing a Phase II clinical trial plan and... Read More

SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program and strategy in this letter to investors. NanoViricides is developing a unique direct-acting antiviral drug that mimics the host cell and thereby is designed to disable the virus particle from infecting... Read More

SHELTON, CT / ACCESSWIRE / July 24, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today reminds the strong safety and effectiveness against coronaviruses demonstrated by its lead clinical drug candidate NV-387. "President Joe Biden has thankfully recovered from the bout of COVID caused by a new variant," said Anil R. Diwan, PhD,... Read More

SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, discusses its development program for NV-387, a single drug that has shown activity against many respiratory viral infections in animal models, enabling human clinical trials for a number of indications. There are several viruses that continue to cause... Read More

SHELTON, CT / ACCESSWIRE / July 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its current assets and plans towards becoming a successful pharmaceutical company intending to revolutionize the treatment of viral infections. NV-387, our lead broad-spectrum antiviral drug candidate has completed Phase I clinical trial in... Read More

SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad-spectrum antiviral NV-387 could be an important weapon against bird flu H5N1 viruses. NanoViricides has recently found that its host-mimetic clinical drug candidate NV-387 was substantially superior to the three approved drugs... Read More

SHELTON, CT / ACCESSWIRE / June 20, 2024 / NanoViricides, Inc. (NYSE AmerIcan.:NNVC) (the "Company"), a clinical stage company and global leader in broad-spectrum antiviral nanomedicines, reports that the ultra-broad-spectrum antiviral NV-387, a clinical Phase II stage drug candidate, was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model. "We believe that the lung... Read More

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT / ACCESSWIRE / June 11, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports that its clinical stage lead nanoviricide broad-spectrum antiviral drug candidate, NV-387, results... Read More

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT / ACCESSWIRE / June 4, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports on the highly desirable blood concentration profile of its lead clinical stage broad-spectrum... Read More

Novel Host-Mimetic, Virus Killing Technology Platform SHELTON, CT / ACCESSWIRE / May 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its development of a first-in-class, broad-spectrum antiviral agent that could revolutionize treatment of viral infections including RSV, COVID, Influenzas and other viruses. "Resistance... Read More

SHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports that it has engaged Aagami, Inc. for business development, specifically to seek licensing and partnering opportunities for our assets and platform technology. The Company is currently seeking licensing and partnering opportunities for its key... Read More

NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others SHELTON, CT / ACCESSWIRE / May 20, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the strong antiviral activity of NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when... Read More

NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection SHELTON, CT / ACCESSWIRE / May 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending March 31, 2024 with the Securities and Exchange Commission (SEC) on Tuesday, May 14, 2024.... Read More

Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE / May 14, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that antiviral activity of NV-387 against RSV/A2 is strong enough to have resulted in full survival of lethally infected animals was achieved. In this study,... Read More

SHELTON, CT / ACCESSWIRE / May 10, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, will be attending the EF Hutton Annual Global Conference, which will be held at The Plaza Hotel in New York, NY on Wednesday, May 15, 2024. Event EF Hutton Annual Global... Read More

NV-387 Possesses Strong Orthopoxvirus Activity Relevant to Both Sexual and Inhalation Modes of Transmission, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes activity against orthopoxvirus family (Smallpox/Mpox), with both... Read More

NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 6, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes Influenza A viruses, possibly including Bird Flu H5N1 virus as well.... Read More

SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon. The Phase 1 clinical trial, protocol number KM-NVCoV2-001, which received approval from the regulatory agency in India for healthy as well as COVID-19... Read More

SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending December 31, 2023 with the Securities and Exchange Commission (SEC) on Wednesday, February 14, 2024. The report can be accessed at the SEC website at... Read More

SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, explains that the demonstration of strong safety and tolerability of NV-CoV-2 oral drug products has implications beyond COVID, setting the Company up for long term success and growth. NV-CoV-2 drugs contain the... Read More

SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the healthy subjects part of the Phase 1a/1b Clinical Trial of NV-CoV-2 was completed successfully. No adverse events were reported in any of the multiple ascending dose cohorts, confirming the... Read More

SHELTON, CT / ACCESSWIRE / January 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that it is presenting at Biotech Showcase™ 2024. Event Information: Event NanoViricides Presentation at the Biotech Showcase, San Fransisco Day & Date Tuesday, January 9, 2024 Time, Track & Room... Read More

SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Single-Ascending Dose part of the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's broad-spectrum antiviral drug, was completed successfully. Recruitment for the... Read More

SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending September 30, 2023 with the Securities and Exchange Commission (SEC) on Tuesday, November 14, 2023. The report can be accessed at the SEC website or by clicking here . Financial Status - Sufficient Funds to Conduct Clinical... Read More

SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reports that its broad-spectrum antiviral drug candidate, NV-387 was highly effective in an animal model that is used in drug development for MPox and Smallpox virus infections in humans. NV-387 is currently in Phase... Read More

SHELTON, CT / ACCESSWIRE / October 16, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023 with the Securities and Exchange Commission (SEC) on Friday, October 13, 2023. The report can be accessed at the SEC website . We reported that, as of June 30, 2023, we had cash and cash equivalent current assets balance of... Read More

SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the Partnership Opportunities in Drug Delivery (PODD) Conference in Boston, MA, on October 16, 2023 at 6:07pm ET in Track 2B. Dr. Diwan will present a talk entitled "Revolutionizing Antiviral Treatments - Orally Available... Read More

SHELTON, CT / ACCESSWIRE / August 21, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's broad-spectrum antiviral drug, is progressing successfully. Healthy Volunteers Recruitment for Phase 1a and Phase 1b is... Read More

SHELTON, CT / ACCESSWIRE / July 11, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the strong effectiveness of its broad-spectrum antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with RSV (Respiratory Syncytial Virus). NV-387 Can Advance... Read More

SHELTON, CO / ACCESSWIRE / July 6, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily. NanoViricides is a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform. NV-CoV-2 (API NV-387), our lead drug candidate for the treatment of... Read More

SHELTON, CT / ACCESSWIRE / June 29, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. "We believe that the start of the Phase 1a/1b safety and efficacy clinical trial is an important milestone not only for NanoViricides and... Read More

SHELTON, CT / ACCESSWIRE / May 31, 2023 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET. Event BIO International Convention Dates June 5-8, 2023 Location Boston Convention & Exhibition Center (BCEC), Boston, MA, USA. Website... Read More

SHELTON, CT / ACCESSWIRE / May 16, 2023 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023 with the Securities and Exchange Commission (SEC) on Monday, May 15, 2023. The report can be accessed at the SEC website (... Read More

SHELTON, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- (via IBN) -- NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announces that Anil R. Diwan, Ph.D., President of the Company will be presenting at The Inaugural EF Hutton Global Conference, which will be held on May 10-11, 2023, at the... Read More

SHELTON, CT / ACCESSWIRE / April 25, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that it is exploring additional antiviral applications for NV-387, the active pharmaceutical ingredient used in NV-CoV-2, the Company's COVID clinical drug candidate. NV-387 has been... Read More

SHELTON, CT / ACCESSWIRE / April 17, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in nanomedicines against viruses, announced today that it has shipped the drug products for impending clinical trials of NV-CoV-2, its COVID drug candidate, to its collaborator, Karveer Meditech Pvt. Ltd., Kolhapur, India ("Karveer"). Karveer has already successfully obtained required... Read More

SHELTON, CT / ACCESSWIRE / April 4, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in nanomedicines against viruses, announced today that it has executed a License Agreement with Karveer Meditech Pvt. Ltd., Kolhapur, India ("Karveer"). Under this Agreement, Karveer has the right to commercialize the Company's COVID drugs NV-CoV-2 and NV-CoV-2-R in India. To enable commercialization, Karveer... Read More

SHELTON, CT / ACCESSWIRE / February 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending December 31, 2022 with the Securities and Exchange Commission (SEC) on Tuesday, February 14, 2023. The report can be accessed at the SEC website (... Read More

SHELTON, CT / ACCESSWIRE / January 4, 2023 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the Biotech Showcase™ 2023 Conference in San Fransisco on Monday, January 9th at 10:30pm PT. Event Biotech Showcase™ 2023 Conference Dates January 9-11, 2023 Location Hilton San Fransisco, Union Square Website... Read More

SHELTON, CT / ACCESSWIRE / December 5, 2022 / NanoViricides, Inc. (NYSE Amer. NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET. The presentation will be webcast and can be seen at https://www.wsw.com/admin/link/presenter.aspx?429387459 . Event RHK Capital Disruptive Growth... Read More